adefovir dipivoxil (Hepsera)

Small molecule

DiscontinuedHBV polymerase (reverse transcriptase)No recent registered activity
WithdrawnUS approval

Evidence outlook · regulatory status

US approval withdrawn: Chronic Hepatitis B (FDA, approved 2002-09-20)

The FDA approved this product and later withdrew the approval, so it has no current US approval. Development was discontinued on 2024-07-03, as a strategic decision by the sponsor. The trials below are the product's evidence history.

Source for the program status

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

Phase 3 (17)
Other / comorbidity
NCT02327416 · Tongji Hospital
2014-10 – 2019-06 · Hepatitis B, Chronic
What this study did
NCT00661076 · Hoffmann-La Roche
2008-08 – 2011-05 · Hepatitis B, Chronic
What this study did
NCT00095121 · Gilead Sciences
2004-06 – 2010-04 · Chronic Hepatitis B
What this study did
NCT00640588 · Novartis Pharmaceuticals
2008-03 – 2009-12 · Hepatitis B, Chronic
What this study did
NCT00496002 · Pharmasset
started 2007-08 · Chronic Hepatitis, Hepatitis B
What this study did
NCT00496158 · Pharmasset
started 2007-08 · Chronic Hepatitis, Hepatitis B
What this study did
NCT00376259 · Novartis
2007-01 – 2008-08 · Hepatitis B
What this study did
NCT00096785 · Bristol-Myers Squibb
2004-12 – 2008-04 · Hepatitis B, Chronic Disease
What this study did
NCT00316719 · GlaxoSmithKline
2006-01 – 2008-01 · Chronic Hepatitis B
What this study did
NCT00115245 · Novartis
2004-11 – 2006-08 · Chronic Hepatitis B
What this study did
NCT00071201 · Gilead Sciences
2003-06 – 2006-03 · Chronic Hepatitis B
What this study did
NCT00002220 · Merck Sharp & Dohme LLC
— · HIV Infections
What this study did
NCT00001082 · National Institute of Allergy and Infectious Diseases (NIAID)
1996-12 – 1999-08 · Cytomegalovirus Infections, HIV Infections
What this study did
Phase 2 (16)
Other / comorbidity
NCT00051077 · National Institute of Allergy and Infectious Diseases (NIAID)
— · HIV Infections, Hepatitis B, Hepatitis C
What this study did
NCT00960518 · Tongji University
2009-08 – 2015-08 · Hepatitis B Virus, Hepatocellular Carcinoma
What this study did
NCT00023309 · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
2001-08 – 2013-08 · HBV (Hepatitis B Virus), Hepatitis B, Hepatitis
What this study did
NCT00230490 · Bausch Health Americas, Inc.
2005-06 – 2007-05 · Hepatitis B, Chronic
What this study did
NCT00230503 · Bausch Health Americas, Inc.
2004-06 – 2006-12 · Hepatitis B, Chronic
What this study did
NCT00033163 · National Institute of Allergy and Infectious Diseases (NIAID)
est. completion 2005-05 · HIV Infections, Hepatitis B
What this study did
NCT00644761 · Gilead Sciences
2004-02 – 2005-05 · Hepatitis B
What this study did
NCT00013702 · National Institute of Allergy and Infectious Diseases (NIAID)
2001-03 – 2004-02 · Hepatitis B, HIV Infection
What this study did
NCT00000885 · National Institute of Allergy and Infectious Diseases (NIAID)
est. completion 2003-06 · HIV Infections
What this study did
NCT00001087 · National Institute of Allergy and Infectious Diseases (NIAID)
est. completion 2000-07 · HIV Infections
What this study did
NCT00000912 · National Institute of Allergy and Infectious Diseases (NIAID)
est. completion 2000-05 · HIV Infections
What this study did
Phase 1/2 (2)
Other / comorbidity
NCT01146808 · Columbia University
2006-03 – 2012-09 · Hepatitis B, Liver Transplantation
What this study did
NCT00645294 · Gilead Sciences
2003-02 – 2003-08 · Hepatitis B
What this study did
Phase 1 (9)
Other / comorbidity
NCT03801759 · Akebia Therapeutics
2018-07-20 – 2018-09-30 · Drug Interaction Potentiation
What this study did
NCT01353742 · GlaxoSmithKline
2011-02-21 – 2011-04-12 · Hepatitis B, Chronic
What this study did
NCT00000843 · National Institute of Allergy and Infectious Diseases (NIAID)
— · HIV Infections
What this study did
NCT00002346 · Gilead Sciences
— · HIV Infections
What this study did
NCT00002206 · Gilead Sciences
— · HIV Infections
What this study did
NCT00002326 · Gilead Sciences
— · HIV Infections
What this study did
Phase 4 (36)
Other / comorbidity
NCT02743260 · University of Cologne
2016-04 – 2017-12 · Healthy
What this study did
NCT02826070 · Nanfang Hospital, Southern Medical University
2015-04 – 2017-10 · Hepatitis B, Chronic
What this study did
NCT02327689 · Asian-Pacific Alliance of Liver Disease, Beijing
2015-01 – 2017-07 · Hepatitis B, Chronic, Fibrosis
What this study did
NCT02482272 · Asan Medical Center
2015-05 – 2017-05 · Hepatitis B, Chronic
What this study did
NCT02560649 · Ruijin Hospital
2015-05 – 2017-02 · Chronic Hepatitis B
What this study did
NCT00810524 · Sun Yat-sen University
2007-01 – 2017-01 · Hepatitis B, Chronic
What this study did
NCT01834508 · Nanfang Hospital, Southern Medical University
2013-03 – 2016-12 · Chronic Hepatitis B
What this study did
NCT01829685 · Nanfang Hospital, Southern Medical University
2013-03 – 2016-06 · Chronic Hepatitis B, Inadequate Response, Nucleos(t)Ide Analogues Treatment
What this study did
NCT01799486 · Lin Bingliang
2013-02 – 2015-03 · HBV-related Liver Cirrhosis
What this study did
NCT01264133 · Bukwang Pharmaceutical
2009-09 – 2014-12 · Chronic Hepatitis B
What this study did
NCT01341743 · Nanfang Hospital, Southern Medical University
2010-12 – 2014-12 · Hepatitis B
What this study did
NCT00922207 · Hoffmann-La Roche
2010-05-07 – 2014-09-29 · Hepatitis B, Chronic
What this study did
NCT00986778 · Bristol-Myers Squibb
2009-12 – 2014-06 · Hepatitis B, Chronic
What this study did
NCT01521975 · Third Affiliated Hospital, Sun Yat-Sen University
2011-01-01 – 2014-05-30 · Hepatitis B, Chronic
What this study did
NCT01693679 · Shao-quan Zhang
2012-09 – 2014-04 · HBV-related Liver Cirrhosis
What this study did
NCT01595633 · Yonsei University
2012-03 – 2014-02 · Chronic Hepatitis B
What this study did
NCT01546116 · Korea University
2010-02 – 2014-02 · Chronic Hepatitis B
What this study did
NCT01263002 · Bukwang Pharmaceutical
2010-06 – 2013-09 · Hepatitis B Associated Hepatocellular Carcinoma
What this study did
NCT01088009 · Nanfang Hospital, Southern Medical University
2010-03 – 2013-05 · Compensated Chronic Hepatitis B
What this study did
NCT01086085 · Hoffmann-La Roche
2010-04 – 2013-03 · Hepatitis B, Chronic
What this study did
NCT01264354 · Bukwang Pharmaceutical
2010-03 – 2013-02 · Chronic Hepatitis B
What this study did
NCT00531167 · Korea University
2007-04 – 2012-10 · Chronic Hepatitis B
What this study did
NCT01023217 · Asan Medical Center
2009-11 – 2012-09 · Hepatitis B, Chronic
What this study did
NCT00409019 · Novartis Pharmaceuticals
est. completion 2011-03 · Chronic Hepatitis B
What this study did
NCT00718887 · Bristol-Myers Squibb
2008-07 – 2011-01 · Hepatitis B, Chronic
What this study did
NCT00798460 · Inje University
2008-12 – 2010-11 · Chronic Hepatitis B
What this study did
NCT00347009 · GlaxoSmithKline
2005-05 – 2009-09 · Hepatitis B, Chronic, Cirrhosis, Fibrosis, Chronic Hepatitis B
What this study did
NCT00324961 · GlaxoSmithKline
2006-01 – 2009-01 · Chronic Hepatitis B
What this study did
NCT00441974 · GlaxoSmithKline
2006-12 – 2008-09 · Chronic Hepatitis B
What this study did
NCT00403585 · GlaxoSmithKline
2006-07 – 2008-04 · Hepatitis B, Chronic, Chronic Hepatitis B
What this study did
NCT00187746 · University of California, San Francisco
2005-08 – 2008-04 · Other Conditions That May Be A Focus of Clinical Attention
What this study did
NCT00230477 · University of Washington
2003-04 – 2007-08 · Hepatitis B
What this study did
NCT01205165 · GlaxoSmithKline
2004-12-17 – 2006-04-28 · Hepatitis B, Chronic
What this study did
Early phase / not applicable (8)
Other / comorbidity
NCT00973219 · Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
2009-09 – 2019-10 · Chronic Hepatitis B
What this study did
NCT01139203 · Shanghai Jiao Tong University School of Medicine
2009-08 – 2012-12 · Liver Transplantation, Hepatitis B
What this study did
NCT00158704 · Gilead Sciences
2002-01 – 2005-01 · Hepatitis B
What this study did
NCT00000892 · National Institute of Allergy and Infectious Diseases (NIAID)
est. completion 1999-08 · HIV Infections
What this study did
Used as active comparator (18)

Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.

Phase 3 (8)
Other / comorbidity
NCT03236584 · Uijeongbu St. Mary Hospital
2015-09-01 – 2019-03-30 · Proportion of Patients With a Sustained Virological Response (Serum HBV DNA <20 IU/mL) at Week 48
What this study did
NCT01300234 · GlaxoSmithKline
2011-03-30 – 2016-12-06 · Hepatitis B
What this study did
NCT00116805 · Gilead Sciences
2005-06 – 2016-01 · Chronic Hepatitis B
What this study did
NCT00117676 · Gilead Sciences
2005-02 – 2016-01 · Chronic Hepatitis B
What this study did
NCT00672867 · Bukwang Pharmaceutical
2007-12 – 2014-09 · Patients With LC-B
What this study did
NCT00065507 · Bristol-Myers Squibb
2003-08 – 2013-05 · Hepatitis B
What this study did
NCT01192854 · Eisai Co., Ltd.
2010-02 – 2011-05 · Chronic Hepatitis B
What this study did
NCT00371761 · Merck Sharp & Dohme LLC
2006-09 – 2009-02 · Hepatitis B, Chronic (CHB)
What this study did
Phase 2 (2)
Other / comorbidity
NCT02965859 · Guangzhou Yipinhong Pharmaceutical CO.,LTD
2012-12 – 2018-12 · Chronic Hepatitis B
What this study did
NCT00753467 · Huntington Medical Research Institutes
2008-09 – 2009-08 · Hepatitis B
What this study did
Phase 1 (1)
Other / comorbidity
NCT00513968 · Genexine, Inc.
2007-07 – 2010-12 · Chronic Hepatitis B
What this study did
Phase 4 (7)
Other / comorbidity
NCT03084250 · Shanghai Nanhui Nanhua Hospital
2017-03-10 – 2023-12-01 · Hepatitis B
What this study did
NCT01491295 · Taipei Veterans General Hospital, Taiwan
2012-09 – 2019-12 · Chronic Hepatitis B
What this study did
NCT01732367 · Keimyung University Dongsan Medical Center
2012-11 – 2016-04 · Chronic Hepatitis B
What this study did
NCT01597934 · Yonsei University
2012-08 – 2014-05 · Chronic Hepatitis B
What this study did
NCT00641082 · Bukwang Pharmaceutical
2008-02 – 2012-03 · HBeAg(-) Chronic Hepatitis B With Compensated Liver Function
What this study did
NCT00606099 · Novartis
2007-11 – 2009-11 · Chronic Hepatitis B
What this study did
Appears in other studies (2)

Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.

Phase 3 (1)
Other / comorbidity
NCT02366247 · Jiangsu Hansoh Pharmaceutical Co., Ltd.
2013-08 – 2016-02 · Hepatitis B, Chronic
What this study did
Phase 2 (1)
Other / comorbidity
NCT02366208 · Jiangsu Hansoh Pharmaceutical Co., Ltd.
2011-05 – 2013-08 · Hepatitis B, Chronic
What this study did

Competitive landscape

7 other tracked programmes target this mechanism, 6 of them ahead of this one.

This drug's own stage for Chronic Hepatitis B: Discontinued. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Adefovir Dipivoxil (Hepsera): this drugDiscontinuedSmall moleculeHBV polymerase (reverse transcriptase)not yet gradedNo reviewed efficacy summary in this indication
Entecavir (Baraclude)ApprovedSmall moleculeHBV polymerase (reverse transcriptase)not yet gradedNo reviewed efficacy summary in this indication
Hepatitis B Immune Globulin (HepaGam B)ApprovedProtein / enzyme therapeuticHBsAgnot yet gradedNo reviewed efficacy summary in this indication
Interferon Alfa-2b (Intron A)ApprovedBiologic (subtype unspecified)Type I interferon receptornot yet gradedNo reviewed efficacy summary in this indication
Lamivudine (Epivir-HBV)
ApprovedUS marketing discontinued
Small moleculeHBV polymerase (reverse transcriptase)not yet gradedNo reviewed efficacy summary in this indication
Peginterferon Alfa-2a (Pegasys)Approved—Type I interferon receptorPartial signalFeatured results are non-efficacy only in this race
Tenofovir Alafenamide (Vemlidy)ApprovedSmall moleculeHBV polymerase (reverse transcriptase)Reliable signalFeatured results are non-efficacy only in this race
Tenofovir Disoproxil Fumarate (Viread)ApprovedSmall moleculeHIV reverse transcriptase (RT)Reliable signal
NCT00116805: Percentage of Participants With HBV DNA < 400 Copies/mL and Histological Improvement (2-point Reduction in Knodell Necroinflammatory Score Without Worsening in Knodell Fibrosis Score) at Week 48 (Baseline; Week 48): TDF-TDF 66.5 percentage of participants | ADV 10 mg 12.2 percentage of participants
NCT00117676: Percentage of Participants With HBV DNA < 400 Copies/mL and Histological Improvement (2-point Reduction in Knodell Necroinflammatory Score Without Worsening in Knodell Fibrosis Score) at Week 48 (Baseline; Week 48): TDF-TDF — Yes: 70.8 percentage of participants; No: 29.2 percentage of participants | ADV-TDF — Yes: 48.8 percentage of participants; No: 51.2 percentage of participants
Besifovir Dipivoxil (Besivo)Phase 3Small moleculeHBV polymerase (reverse transcriptase)Partial signal
NCT01937806: Primary endpoint at week 48: 80.9% with besifovir vs 84.9% with tenofovir disoproxil fumarate met the virologic response endpoint, showing non-inferiority (Ahn et al., Clin Gastroenterol Hepatol 2019).
Hepatitis B Immune Globulin (I.V.-Hepabig)Phase 3Polyclonal Antibody (human Hepatitis B Immunoglobulin)HBsAgnot yet gradedNo reviewed efficacy summary in this indication
Tenofovir Amibufenamide (Hengmu)Phase 3Small moleculeHBV polymerase (reverse transcriptase)not yet gradedNo reviewed efficacy summary in this indication
TQA3605Phase 3—HBV core proteinnot yet gradedNo reviewed efficacy summary in this indication
TVAX-008Phase 3VaccineHepatitis B virus antigens (HBsAg + HBcAg)not yet gradedNo reviewed efficacy summary in this indication
AHB-171Phase 2RNA / oligonucleotideHBV RNAnot yet gradedNo reviewed efficacy summary in this indication
Daplusiran / TomligisiranPhase 2RNA / oligonucleotideHBV RNA (X and S transcripts)not yet gradedNo reviewed efficacy summary in this indication
EnvafolimabPhase 2Monoclonal antibodyPD-L1not yet gradedNo reviewed efficacy summary in this indication
HepalatidePhase 2PeptideNTCPnot yet gradedNo reviewed efficacy summary in this indication
Libevitug (HH-003)Phase 2Monoclonal antibodyHBV/HDV large envelope protein (PreS1 domain)not yet gradedNo reviewed efficacy summary in this indication
MetacavirPhase 2Small moleculeHBV reverse transcriptase (nucleoside analog)not yet gradedNo reviewed efficacy summary in this indication
REP 2139-MgPhase 2—HBsAg release (nucleic acid polymer)not yet gradedNo reviewed efficacy summary in this indication
T101Phase 2Biologic (subtype unspecified)HBV core, polymerase and envelope antigensnot yet gradedNo reviewed efficacy summary in this indication
TQA3810Phase 2—TLR8not yet gradedNo reviewed efficacy summary in this indication
CRMA-1001Phase 1/2Gene therapy / editingHBV genome (cccDNA and integrated DNA)not yet gradedNo reviewed efficacy summary in this indication
HepadvaxPhase 1/2VaccineHBsAg (PreS) immunizationnot yet gradedNo reviewed efficacy summary in this indication
Human Serum Albumin / Interferon Alpha2b Fusion ProteinPhase 1/2Biologic (subtype unspecified)Type I interferon receptornot yet gradedNo reviewed efficacy summary in this indication
LW231Phase 1/2——not yet gradedNo reviewed efficacy summary in this indication
PA1010Phase 1/2——not yet gradedNo reviewed efficacy summary in this indication
TQA3038Phase 1/2——not yet gradedNo reviewed efficacy summary in this indication
ACT201Phase 1RNA / oligonucleotideHBsAgnot yet gradedNo reviewed efficacy summary in this indication
CB06-036Phase 1—TLR8not yet gradedNo reviewed efficacy summary in this indication
DA-2803Phase 1——not yet gradedNo reviewed efficacy summary in this indication
Entecavir (Cavir)
Phase 1(overall)
Small moleculeHBV polymerase (reverse transcriptase)not yet gradedNo reviewed efficacy summary in this indication
HECN30227Phase 1——not yet gradedNo reviewed efficacy summary in this indication
SA1211Phase 1RNA / oligonucleotideHepatitis B virus RNA (dual-target siRNA)not yet gradedNo reviewed efficacy summary in this indication
TVAX-028Phase 1——not yet gradedNo reviewed efficacy summary in this indication
Obeticholic Acid (Ocaliva)Discontinued—FXRnot yet gradedNo reviewed efficacy summary in this indication
PamrevlumabDiscontinuedMonoclonal antibodyCTGFnot yet gradedNo reviewed efficacy summary in this indication
Telbivudine (Tyzeka)Discontinued—HBV polymerase (reverse transcriptase)Partial signal
NCT00076336: Protocol composite at week 52 (HBV DNA <10,000 copies/mL, normal ALT, Child-Turcotte-Pugh score improved or stable), telbivudine vs lamivudine, ITT missing=failure: 56.2% vs 54.0%, non-inferiority not achieved (Chan et al., Aliment Pharmacol Ther 2012). missed

Upcoming events

No upcoming readouts on record for this asset.